Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies od Long Jiang (14956159)

Hasła przedmiotowe:

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies od Long Jiang (14956159)

Hasła przedmiotowe:

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies od Long Jiang (14956159)

Hasła przedmiotowe:

Supplementary Tables from Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib od Xiangyu Zeng (17314920)

Hasła przedmiotowe:

Table S5 from The RNA m⁶A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression od Yun-Guang Hong (14960966)

Hasła przedmiotowe:

Table S3 from The RNA m⁶A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression od Yun-Guang Hong (14960966)

Hasła przedmiotowe:

Table S2 from The RNA m⁶A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression od Yun-Guang Hong (14960966)

Hasła przedmiotowe:

Table S4 from The RNA m⁶A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression od Yun-Guang Hong (14960966)

Hasła przedmiotowe:

Table S1 from The RNA m⁶A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression od Yun-Guang Hong (14960966)

Hasła przedmiotowe:

Table S6 from The RNA m⁶A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression od Yun-Guang Hong (14960966)

Hasła przedmiotowe:

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy od Zev A. Wainberg (15047031)

Hasła przedmiotowe:

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans od Yuanqing Ma (15052437)

Hasła przedmiotowe:

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans od Yuanqing Ma (15052437)

Hasła przedmiotowe:

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans od Yuanqing Ma (15052437)

Hasła przedmiotowe:

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans od Yuanqing Ma (15052437)

Hasła przedmiotowe:

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans od Yuanqing Ma (15052437)

Hasła przedmiotowe:

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans od Yuanqing Ma (15052437)

Hasła przedmiotowe:

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans od Yuanqing Ma (15052437)

Hasła przedmiotowe:

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans od Yuanqing Ma (15052437)

Hasła przedmiotowe:

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute My... od Amir T. Fathi (15313195)

Hasła przedmiotowe: